|
시장보고서
상품코드
1789388
세계의 세포 리프로그래밍 시장 : 제품별, 세포원별, 기술별, 용도별, 최종사용자별, 지역별Cell Reprogramming Market, By Product, By Cell Type, By Source of Cells, By Technology, By Application, By End User, By Geography |
||||||
세포 리프로그래밍 시장은 2025년에는 4억 170만 달러, 2032년에는 7억 1,560만 달러에 이르고, 2025-2032년 CAGR은 8.6%를 나타낼 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 4억 170만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 : 2025-2032년 | 8.60% | 2032년 금액 예측 | 7억 1,560만 달러 |
세계 리프로그래밍 시장은 재생의료와 생명공학의 혁명적인 개척지이며, 연구자와 임상의가 세포치료와 질병치료에 접근하는 방식을 근본적으로 변화시키고 있습니다. 분화된 세포를 다능성 상태로 되돌리거나 다른 세포 유형으로 직접 전환하는 과정인 세포 초기화는 전례 없는 치료 가능성을 가능케 하는 기초 기술로 부상하고 있습니다. 이 정교한 생물학적 방법은 인공만능줄기세포(iPSC) 제작, 직접 초기화, 트랜스분화 과정 등 다양한 방법론을 포함하고 있으며, 각 방법론은 맞춤형 의료에 적용될 수 있는 고유한 이점을 제공합니다.
이 시장은 전 세계 학술기관, 제약회사, 생명공학 기업에서 세포 초기화를 촉진하는 연구 도구, 시약, 장비, 서비스 등의 종합적인 생태계를 포괄하고 있습니다. 정밀의료와 재생치료에 대한 관심이 높아짐에 따라, 세포 초기화 기술은 신약 파이프라인, 질병 모델링 플랫폼, 그리고 지금까지 치료할 수 없었던 질병에 대한 잠재적 치료 중재에 점점 더 많이 통합되고 있습니다. 첨단 유전자 편집 기술, 리프로그래밍 프로토콜의 개선, 세포 가소성 메커니즘에 대한 이해 강화의 융합으로 이 시장은 차세대 의료 혁신의 최전선에 위치하며, 여러 치료 영역에 걸친 치료 패러다임을 재구성할 것으로 기대됩니다.
시장 역학
세계 리프로그래밍 시장은 몇 가지 강력한 촉진요인에 힘입어 견조한 확장 궤도를 유지하고 있습니다. 만성질환, 유전성 질환, 노화 관련 질환의 유병률 증가로 인해 세포 초기화 기술이 독자적으로 대응할 수 있는 혁신적인 치료법에 대한 수요가 증가하고 있습니다. 재생의료 연구에 대한 투자 개척은 정부의 자금 지원 이니셔티브와 유리한 규제 프레임워크와 결합하여 시장 개발을 크게 가속화하고 있습니다. 비통합적 접근 방식과 화학적으로 정의된 프로토콜을 포함한 리프로그래밍 방법의 기술적 발전은 안전성에 대한 우려를 줄이면서 효율성을 높여 상업적 실행 가능성을 확대할 수 있습니다.
제약업계에서는 개인 맞춤형 의료와 환자 맞춤형 치료 솔루션에 대한 관심이 높아지면서 iPSC 기반 약물 스크리닝 및 독성 검사 플랫폼의 채택이 증가하고 있습니다. 그러나 세포 기반 치료법에 대한 복잡한 규제 경로, 일관된 초기화 효율을 달성하기 위한 기술적 과제, 전문 실험실 인프라 구축에 따른 비용 장벽 등 시장 성장을 저해하는 요인이 존재하고 있습니다. 줄기세포 연구를 둘러싼 윤리적 문제와 초기화 프로토콜의 표준화가 제한적이라는 점도 시장 진입의 장벽으로 작용하고 있습니다. 초기화 세포의 유전체 불안정성 및 종양 형성 가능성에 대한 안전성에 대한 우려는 규제 및 상업적 이슈가 되고 있습니다. 새로운 기회는 특히 질병 모델링, 신약개발 촉진, 기성 세포치료제 개발에서의 응용 확대를 통해 큰 성장 가능성을 보여주고 있습니다. 생명공학 기업과 대형 제약사와의 전략적 파트너십은 기술 이전 및 상업화 경로를 촉진합니다. 신흥 시장에서의 채택 확대와 재생의료의 장점에 대한 인식이 높아짐에 따라 시장 진출기업들에게 새로운 수익원과 시장 확대의 기회를 창출하고 있습니다.
본 조사의 주요 특징
- 세계의 세포 초기화 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 세포 초기화 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 세포 초기화 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- Porter's Five Forces 분석
- 인수합병(M&A) 시나리오
- 산업 동향
제4장 세계의 세포 리프로그래밍 시장, 제품별, 2020-2032년
- 서론
- 기기
- 소모품과 키트(리프로그래밍 키트, 배지 및 시약, 성장 요인, 배양 용기 등)
- 소프트웨어(세포 분석 소프트웨어, 데이터 관리 플랫폼, 프로세스 제어 소프트웨어)
- 서비스(리프로그래밍 서비스, 세포주 개발, 품질 관리 검사)
제5장 세계의 세포 리프로그래밍 시장, 세포 유형별, 2020-2032년
- 서론
- 체세포
- 배성줄기세포
- 성체줄기세포
- 암 줄기세포
- 중간엽 줄기세포
제6장 세계의 세포 리프로그래밍 시장, 세포원별, 2020-2032년
- 서론
- 인간세포
- 동물세포
제7장 세계의 세포 리프로그래밍 시장, 기술별, 2020-2032년
- 서론
- Sendai Virus-based Reprogramming
- mRNA Reprogramming
- Episomal Reprogramming
- Small Molecule-based Reprogramming
- CRISPR or Cas9-based Reprogramming
- 기타 리프로그래밍 기술
제8장 세계의 세포 리프로그래밍 시장, 용도별, 2020-2032년
- 서론
- 줄기세포 연구
- 질환 모델
- 독성 검사
- 약제 검사
- 재생의료
제9장 세계의 세포 리프로그래밍 시장, 최종사용자별, 2020-2032년
- 서론
- 제약 및 바이오테크놀러지 기업
- 병원 및 클리닉
- 계약 연구기관(CRO)
- 정부기관 및 비영리 단체
- 기타(학술연구기관 등)
제10장 세계의 세포 리프로그래밍 시장, 지역별, 2020-2032년, 금액(100만 달러)
- 서론
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN 국가
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제11장 경쟁 구도
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
제12장 애널리스트 추천 사항
- 기회
- COP(Coherent Opportunity Map)
제13장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사에 대해
Cell Reprogramming Market is estimated to be valued at USD 401.7 Mn in 2025 and is expected to reach USD 715.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 401.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.60% | 2032 Value Projection: | USD 715.6 Mn |
The global cell reprogramming market represents a revolutionary frontier in regenerative medicine and biotechnology, fundamentally transforming how researchers and clinicians approach cellular therapy and disease treatment. Cell reprogramming, the process of converting differentiated cells back to a pluripotent state or directly into other cell types, has emerged as a cornerstone technology enabling unprecedented therapeutic possibilities. This sophisticated biological technique encompasses various methodologies including induced pluripotent stem cell (iPSC) generation, direct reprogramming, and trans differentiation processes, each offering unique advantages for personalized medicine applications.
The market encompasses a comprehensive ecosystem of research tools, reagents, instruments, and services that facilitate cellular reprogramming across academic institutions, pharmaceutical companies, and biotechnology firms worldwide. With growing emphasis on precision medicine and regenerative therapies, cell reprogramming technologies are increasingly being integrated into drug discovery pipelines, disease modeling platforms, and potential therapeutic interventions for previously untreatable conditions. The convergence of advanced gene editing technologies, improved reprogramming protocols, and enhanced understanding of cellular plasticity mechanisms has positioned this market at the forefront of next-generation medical innovations, promising to reshape treatment paradigms across multiple therapeutic areas.
Market Dynamics
The global cell reprogramming market is propelled by several compelling drivers that collectively fuel its robust expansion trajectory. The increasing prevalence of chronic diseases, genetic disorders, and age-related conditions creates substantial demand for innovative therapeutic approaches that cell reprogramming technologies uniquely address. Growing investments in regenerative medicine research, coupled with supportive government funding initiatives and favorable regulatory frameworks, significantly accelerate market development. Technological advancements in reprogramming methodologies, including non-integrative approaches and chemically-defined protocols, enhance efficiency while reducing safety concerns, thereby expanding commercial viability.
The pharmaceutical industry's intensifying focus on personalized medicine and patient-specific therapeutic solutions drives adoption of iPSC-based drug screening and toxicity testing platforms. However, market growth faces notable restraints including complex regulatory pathways for cell-based therapies, substantial technical challenges in achieving consistent reprogramming efficiency, and significant cost barriers associated with establishing specialized laboratory infrastructure. Ethical considerations surrounding stem cell research, along with limited standardization across reprogramming protocols, create additional market entry barriers. Safety concerns regarding genomic instability and tumorigenic potential of reprogrammed cells continue to pose regulatory and commercial challenges. Nevertheless, emerging opportunities present substantial growth potential, particularly through expanding applications in disease modeling, drug discovery acceleration, and development of off-the-shelf cellular therapies. Strategic partnerships between biotechnology companies and pharmaceutical giants facilitate technology transfer and commercialization pathways. Growing adoption in emerging markets, coupled with increasing awareness of regenerative medicine benefits, creates new revenue streams and market expansion opportunities for industry participants.
Key Features of the Study
- This report provides an in-depth analysis of the global cell reprogramming market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cell reprogramming market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Thermo Fisher Scientific, Merck KGaA, Takara Bio Inc, Lonza Group, FUJIFILM Cellular Dynamics, StemCell Technologies, REPROCELL Inc, Astellas Pharma, Fate Therapeutics, Cynata Therapeutics, Pluri Inc, ViaCyte Inc, BlueRock Therapeutics, Century Therapeutics, and Editas Medicine.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cell reprogramming market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell reprogramming market.
Market Segmentation
- Product Insights (Revenue, USD Mn, 2020 - 2032)
- Instruments
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (CO,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Cell Type Insights (Revenue, USD Mn, 2020 - 2032)
- Somatic Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cancer Stem Cells
- Mesenchymal Stem Cell
- Source of Cells Insights (Revenue, USD Mn, 2020 - 2032)
- Human Cells
- Animal Cells
- Technology Insights (Revenue, USD Mn, 2020 - 2032)
- Sendai Virus-based Reprogramming
- mRNA Reprogramming
- Episomal Reprogramming
- Small Molecule-based Reprogramming
- CRISPR or Cas9-based Reprogramming
- Other Reprogramming Technologies
- Application Insights (Revenue, USD Mn, 2020 - 2032)
- Stem Cell Research
- Disease Modeling
- Toxicology Testing
- Drug Screening
- Regenerative Medicine
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Contract Research Organizations (CROs)
- Government and Non-profit Organizations
- Others (Academic and Research Institutions, etc.)
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cell Reprogramming Market, By Product
- Global Cell Reprogramming Market, By Cell Type
- Global Cell Reprogramming Market, By Source of Cells
- Global Cell Reprogramming Market, By Technology
- Global Cell Reprogramming Market, By Application
- Global Cell Reprogramming Market, By End User
- Global Cell Reprogramming Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cell Reprogramming Market, By Product, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Instruments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (CO,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Reprogramming Workstations
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Cell Reprogramming Market, By Cell Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Somatic Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Embryonic Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Adult Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Cancer Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Mesenchymal Stem Cell
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Cell Reprogramming Market, By Source of Cells, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Human Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Animal Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Cell Reprogramming Market, By Technology, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Sendai Virus-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- mRNA Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Episomal Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Small Molecule-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- CRISPR or Cas9-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Other Reprogramming Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Cell Reprogramming Market, By Application, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Stem Cell Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Drug Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
9. Global Cell Reprogramming Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Goverment and Non-profit Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Academic and Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
10. Global Cell Reprogramming Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takara Bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lonza Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Cellular Dynamics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- StemCell Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- REPROCELL Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cynata Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pluri Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViaCyte Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BlueRock Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Century Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Editas Medicine
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
